SecBot SecBot
6-K ·Filed Nov 9, 2026

CGEN

COMPUGEN LTD
NEUTRAL
Impact 4/10
Horizonmonths Processed7d 19h ago SEC0001178913-26-005086
6-K: Earnings release
Actionable Insight • Neutral

The narrower loss and cash runway into 2029 remove near-term financing risk. The key binary catalyst is MAIA-ovarian data in Q1 2027; positive results could validate COM701 and unlock significant value. Monitor AstraZeneca's rilvegostomig Phase 3 readout in H2 2027 for milestone potential.

DirectionNeutral
Confidencehigh
Horizonmonths

COM701

◆ Mixed Named in this 6-K
Impact
Phase
Phase 1/2
Time to market
At least 3-5 years. COM701 is in Phase 1/2 (MAIA trial); even with positive interim data in Q1 2027, a registrational Phase 3 trial and FDA review would follow, putting potential approval in the 2029-2031 timeframe.
Next catalyst
None dated

What to watchThe next hard catalyst for COM701 is the MAIA-ovarian interim PFS analysis expected by Q1 2027, roughly 4-6 months out. Positive data could drive a significant re-rating given the strong analyst consensus (10 Buy/Strong Buy vs 1 Hold) and ~41% implied upside to the $4.60 mean price target. Negative data would be a major setback for Compugen's wholly-owned pipeline. Monitor for any pre-announcements or delays.

How the stock moved after the report

NEUTRAL VIEWSTOCK BELOW ENTRY AT T+5
Entry
$2.14
T+0 close · Nov 9, 2026 · via day close
Latest settled
−4.67%
T+5 · $2.04
Vs SPY
−2.98%
α at T+5
Next horizon
T+20
in 21d
  1. T+0 · Nov 9 $2.14entry
  2. T+1 · 7d ago −2.34%α −1.97% · $2.09
  3. T+5 · 20h ago −4.67%α −2.98% · $2.04
  4. T+20 · in 21d Pending
  5. T+60 · in 3mo Pending
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Compugen reported Q3 2026 net loss of $5.8M ($0.06 per share), narrower than the $7.0M loss in Q3 2025, on revenue of $3.8M (up from $1.9M). The EPS of -$0.06 beat the consensus estimate of -$0.09. Cash of $117.5M is expected to fund operations into 2029. Key pipeline catalysts include MAIA-ovarian results by end of Q1 2027 and Phase 3 rilvegostomig data from AstraZeneca in H2 2027.

Key Financial Metrics

EPS
−$0.06
est −$0.09 · +33.3%
Revenue
$3.8M
est $975.0K · +291.9% · +102.1% YoY
Rating
beat
Gross Margin
37.2%

Key Facts

  • Q3 2026 net loss of $5.8M ($0.06 per share) vs $7.0M ($0.07) in Q3 2025
  • Revenue of $3.8M vs $1.9M in Q3 2025, driven by Gilead license revenue recognition
  • Cash and equivalents of $117.5M as of Sep 30, 2026; runway into 2029
  • MAIA-ovarian trial (COM701) fully enrolled; results expected by end of Q1 2027
  • AstraZeneca Phase 3 rilvegostomig data from ARTEMIDE-Biliary01 anticipated H2 2027
  • GS-0321 (licensed to Gilead) Phase 1 dose-escalation trial advancing
  • Up to $195M in additional milestones from AstraZeneca; up to $758M from Gilead

Financial Impact

Net loss improved by $1.2M YoY; revenue doubled to $3.8M; cash position $117.5M

revenuenet losscash runway

Risk Factors

  • MAIA-ovarian trial may fail to show statistically significant PFS benefit
  • Reliance on partner AstraZeneca and Gilead for development and commercialization
  • No approved products; pre-revenue stage with ongoing operating losses
  • Israel-based operations subject to geopolitical risk

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
91% bullish (11 analysts)

Investment Themes

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
6-K Filing (Primary)0001178913-26-005086
Document: zk2636367.htm0001178913-26-005086
Document: 0001178913-26-005086-index-headers.html0001178913-26-005086
Document: 0001178913-26-005086-index.html0001178913-26-005086
Document: 0001178913-26-005086.txt0001178913-26-005086
Earnings Context (Synthetic; results releases only)0001178913-26-005086

US Market Status

Market Closed · Opens in 6h 39m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 9, 2026